Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.
Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check19 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.0%
- Check26 days agoChange DetectedThe website has updated the contact details and location information for a study, now indicating it is completed and providing a new revision version, while removing previous details about the study's active status.SummaryDifference2%
- Check33 days agoChange DetectedNew recruiting contacts have been added, including multiple Study Coordinators with various phone numbers, while previous entries related to 'Active, not recruiting' and specific Merck Oncology Clinical Trials Information have been removed.SummaryDifference3%
- Check40 days agoChange DetectedThe website has added new features while removing extensive details about participant groups, interventions, and various data fields available for download.SummaryDifference2%
- Check48 days agoChange DetectedSeveral key health-related links, including those for lung cancer information and clinical trials, have been removed from the website.SummaryDifference0.3%
- Check55 days agoChange DetectedThe website has been updated to version 2.12.2, with numerous new resources added related to lung cancer, including links to MedlinePlus and clinical trial information.SummaryDifference3%
Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.